Table 3.
Comparison of the present study with previous studies on recurrence of rectal cancer.
| References | Year | n | Method of treatment | 3-year OS rate | 5-year OS rate | 3-year LC rate | 5-year LC rate | Late toxicities ≥grade 3 |
|---|---|---|---|---|---|---|---|---|
| Wong et al. (6) | 1998 | 214 | X-ray RT | NA | 5% | NA | 7% | Infection: none, GI: 5.7% |
| Tanaka et al. (33) | 2017 | 32 | X-ray RT | 45% | 23% | 19% | 13% | NA |
| Lee et al. (32) | 2011 | 22 | CCRT | NA | 41% | NA | 56% | NA |
| Cai et al. (27) | 2015 | 71 | CCRT | 37% | NA | 34% | NA | NA |
| Kim et al. (31) | 2008 | 23 | SBRT | NA | 23% | 74% (4-year) | NA | Infection: none, GI: none |
| Franzese et al. (28) | 2017 | 35 | SBRT | 81% | NA | 75% | NA | Infection: none, GI: none |
| Yamada et al. (17) | 2016 | 151 | C-ion RT | 78% | 59% | NA | 88% | Infection: none, GI: 0.7% |
| Shinoto et al. (21) | 2018 | 224 | C-ion RT | 73% | 51% | 93% | 88% | Infection: 3.1%, GI: 0.9% |
| Present study | 28 | C-ion RT | 92% | 58% | 86% | 79% | Infection: 7%, GI: none |
CCRT, concurrent chemoradiotherapy; C-ion RT, carbon ion radiotherapy; GI, gastrointestinal tract; LC, local control; NA, not available; OS, overall survival; RT, radiotherapy; SBRT, stereotactic body radiotherapy.